MRTX News and Press, Mirati Therapeutics Inc. From 10/10/23

2023-10-10 07:30:00 ET Summary After years of buyout rumors, Mirati has finally received a buyout offer. The offer from Bristol-Myers Squibb was disappointing to shareholders who were anticipating a significant buyout premium. Although there is always a possibility of addition...

2023-10-09 13:10:55 ET More on Bristol-Myers Squibb Company , Mirati Therapeutics Bristol-Myers' Mirati Takeover: Pharma Is Either Buying Crown Jewels Or A Dud Bristol-Myers: Out Of Favor (Rating Upgrade) Bristol-Myers Squibb: How Cheap Is Cheap Enough? ...

2023-10-09 13:04:02 ET Bristol-Myers Squibb Co (NYSE: BMY) has decided to spend up to $5.8 billion to acquire Mirati Therapeutics Inc (NASDAQ: MRTX). Shares of both companies are in the red at writing. Bristol-Myers will get to expand its footprint in oncology The all-cash trans...

2023-10-09 12:00:33 ET Summary Bristol-Myers Squibb has announced its acquisition of Mirati Therapeutics and its lead drug candidate KRAZATI for a potential value of $5.8 million. BMY paid a 52% premium to Mirati's share price with other Pharmas - e.g. Sanofi - rumored to be inter...

NEW YORK, NY / ACCESSWIRE / October 9, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Mirati Therapeutics, Inc. (NASDA...

2023-10-09 09:56:59 ET More on Mirati Therapeutics Mirati: Expansion Of Adagrasib With sNDA And Combination Studies Mirati Therapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation Mirati Therapeutics, Inc. (MRTX) Q2 2023 Earnings Call Transcript 4 st...

2023-10-09 09:20:00 ET U.S. stock index futures on Monday pointed to a lower open, with the spotlight on geopolitical conflict following Israel's declaration of war on Hamas after a surprise attack. Wall Street's benchmark index on Friday eventually ended a tumultuous week with a ~0.5% ...

2023-10-09 08:23:30 ET More on InMode, Mirati Therapeutics, etc. InMode: Bullish Support Failed To Materialize InMode: Strong Net Cash Position Sets The Stage For Opportunistic Buybacks InMode: Be Greedy When Others Are Fearful Bristol-Myers Squibb to acquire...

2023-10-09 06:48:53 ET Summary Crude oil and gold futures rise in response to the Israel-Hamas conflict. Analysts expect limited gains in crude oil prices unless the conflict escalates into a regional war. Bristol-Myers Squibb agrees to acquire Mirati Therapeutics for $4.8 bil...

2023-10-08 17:52:39 ET More on Mirati Therapeutics Mirati: Expansion Of Adagrasib With sNDA And Combination Studies Mirati Therapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation Mirati Therapeutics, Inc. (MRTX) Q2 2023 Earnings Call Transcript As F...